A study published in Oncotarget has unveiled a promising new approach to fighting pancreatic cancer, led by Kweku Ofosu-Asante and Nazarius S. Lamango of Florida A&M University. Pancreatic ductal adenocarcinoma is notoriously lethal, largely due to KRAS mutations that help tumors thrive and resist treatment. While some therapies target specific KRAS mutations, many patients are left without options. Enter PCAIs (polyisoprenylated cysteinyl amide inhibitors), experimental compounds designed to mess with abnormal KRAS signaling. In tests on pancreatic cancer cells with KRAS mutations, two PCAIs showed strong anticancer effects, with the lead compound NSL-YHJ-2-27 standing out.

At just 1 µM, NSL-YHJ-2-27 blocked over 90% of cancer cell migration - a finding that suggests it could help curb metastasis. The compounds also lowered levels of monomeric G-proteins, altered tumor-linked gene activity, and trashed the actin cytoskeleton, leaving cancer cells rounded and immobile. But the real twist? Instead of shutting down the MAPK and PI3K/AKT pathways that normally drive cancer growth, PCAIs hyperactivated them, overloading the cells until they self-destructed via apoptosis. Treated cells showed increased reactive oxygen species, activated caspases, and higher levels of the pro-apoptotic protein BAX.

Transcriptomic analyses revealed shifts in gene expression: tumor-suppressing genes ramped up while cancer-promoting ones quieted down. In 3D tumor spheroid models - closer to real tumors - PCAIs caused spheroids to break apart, reduced invasion, and boosted apoptosis. The researchers emphasize that PCAIs can target multiple KRAS mutations, not just one, potentially overcoming limitations of current treatments. “One class of such promising agents is the PCAIs that were designed to target oncogenic G-proteins in a manner that is different from the KRASG12C-targeting drugs,” they note. The study supports further research into PCAIs for pancreatic and other KRAS-driven cancers.